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AbstrAct
Introduction Ceftriaxone is widely used in children in 
the treatment of sepsis. However, concerns have been 
raised about the safety of ceftriaxone, especially in young 
children. The aim of this review is to systematically 
evaluate the safety of ceftriaxone in children of all age 
groups.
Methods and analysis MEDLINE, PubMed, Cochrane 
Central Register of Controlled Trials, EMBASE, CINAHL, 
International Pharmaceutical Abstracts and adverse drug 
reaction (ADR) monitoring systems will be systematically 
searched for randomised controlled trials (RCTs), cohort 
studies, case–control studies, cross-sectional studies, 
case series and case reports evaluating the safety of 
ceftriaxone in children. The Cochrane risk of bias tool, 
Newcastle-Ottawa and quality assessment tools developed 
by the National Institutes of Health will be used for quality 
assessment. Meta-analysis of the incidence of ADRs from 
RCTs and prospective studies will be done. Subgroup 
analyses will be performed for age and dosage regimen.
Ethics and dissemination Formal ethical approval is not 
required as no primary data are collected. This systematic 
review will be disseminated through a peer-reviewed 
publication and at conference meetings.
PrOsPErO registration number CRD42017055428.
IntrOductIOn
Cephalosporins are an important class of 
antibiotics for the treatment of a wide variety 
of infections. As a third-generation ceph-
alosporin, ceftriaxone was approved for 
marketing in the USA in 1984.1 Similar to 
other β-lactam antibiotics, the antibacterial 
activity of ceftriaxone results from the inhibi-
tion of the bacterial cell wall synthesis.2 Since 
ceftriaxone has a strong antibacterial effect, 
long half-life and a good curative effect, it is 
widely used in neonates, infants and children 
in the treatment of sepsis and meningitis.3–7 
Nevertheless, concerns have been raised 
about the safety of ceftriaxone in both adults 
and children.
The Food and Drug Administration (FDA) 
issued an alert in 2007, warning that the 
interaction of ceftriaxone with calcium-con-
taining products may lead to a fatal adverse 
drug reaction (ADR) in neonates and the 
potential for this interaction exists in patients 
of any age.8 The seriousness of these events, 
coupled with their preventable nature, has 
led the FDA and the manufacturer to issue an 
important warning to the medical community 
and change the product labelling.9 Moreover, 
a wide range of other ADRs including liver 
injury have been reported in children and 
some have been added to the Summary of 
Product Characteristics (SPC).10–12 A weak-
ness of SPC changes, however, is that health 
professionals are unaware of changes. Our 
aim is to provide a comprehensive review of 
safety information for ceftriaxone for paedi-
atric patients. Such a review will be useful 
for both individual health professionals and 
groups developing antibiotic guidelines.13 
Although a few reviews have evaluated ADRs 
of ceftriaxone in children in a certain system, 
there is a lack of overall assessment of risk 
estimates of ceftriaxone ADRs and review of 
ceftriaxone safety in children.14 15 The aim 
of this review is to systematically evaluate the 
safety of ceftriaxone in children of all age 
groups.
systEMAtIc rEvIEw quEstIOns
 ► What are the rates and categories of ceftri-
axone ADRs in children?
 ► Is there a subgroup of paediatric patients 
for whom the risk of ceftriaxone ADRs is 
higher and where other antibiotics may 
be more appropriate ?
Safety of ceftriaxone in paediatrics: a 
systematic review protocol
Linan Zeng,1,2 Imti Choonara,3 Lingli Zhang,1,2 Song Xue,4 Zhe Chen,1,2 
Miaomiao He4
To cite: Zeng L, Choonara I, 
Zhang L, et al.  Safety of 
ceftriaxone in paediatrics: 
a systematic review 
protocol. BMJ Open 
2017;7:e016273. doi:10.1136/
bmjopen-2017-016273
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files please visit the 
journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2017- 
016273).
Received 3 February 2017
Revised 23 May 2017
Accepted 6 June 2017
1Department of Pharmacy, 
Evidence-Based Pharmacy 
Center, West China Second 
University Hospital, Sichuan 
University, Chengdu, China
2Key Laboratory of Birth Defects 
and Related Diseases of Women 
and Children, Sichuan University, 
Ministry of Education, Chengdu, 
China
3Academic Division of Child 
Health, University of Nottingham, 
Derbyshire Children’s Hospital, 
Derby, UK
4West China School of 
Pharmacy, Sichuan University, 
Chengdu, China
correspondence to
Dr Lingli Zhang;  
 zhanglingli@ scu. edu. cn
Protocol
strengths and limitations of this study
 ► All types of clinical studies across all paediatric age 
groups will be included without language limitation.
 ► Pharmacovigilance databases such as VigiBase 
(WHO—Uppsala Monitoring Centre) will be searched 
for suspected adverse drug reactions to ceftriaxone.
 ► We will follow the Preferred Reporting Items for 
Systematic Review and Meta-Analysis Protocols and 
use Cochrane quality assessment tools.
 ► The systematic review will include only published 
data.
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MeThods
Rigorous methodology will be adopted in this review 
and will conform to the reporting standards of the 
Preferred Reporting Items for Systematic Reviews and 
Meta-analyses.16 17 This protocol is registered with the 
international prospective register of systematic reviews: 
CRD42017055428.
ElIgIbIlIty crItErIA
Selection criteria will use the Population, Intervention, 
Comparison, Outcome, Study design to determine eligi-
bility of articles. No limitation on language and year of 
publication will be set.
Population
We will include paediatric patients aged from birth to 18 
years and classified according to the International Confer-
ence on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use criteria: 
preterm newborn infants, term newborn infants (0–27 
days), infants and toddlers (28 days to 23 months), chil-
dren (24 months to 11 years) and adolescents (12–18 





Placebo, no intervention or other pharmacological inter-
ventions.
Outcome
The incidence and category of ADRs in paediatric 
patients. WHO—Uppsala Monitoring Centre system will 
be adopted to evaluate the relevance of suspected ADRs 
and ceftriaxone.19
study design
We will include all types of studies including randomised 
controlled trial (RCT), cohort study, case–control study, 
cross-sectional study, case series and case report in the 
systematic review. Only peer-reviewed publications will 
be included. The reason for including all study types 
is that toxicity is poorly reported in RCTs. Previous 
systematic reviews of toxicity of medicines have always 
included case series and case reports.20 21 This will allow 
a comprehensive evaluation of the safety of ceftriaxone 
in paediatric patients. Editorials, conference abstracts 
and reviews will be excluded. Studies evaluating the 
safety of using ceftriaxone during pregnancy and studies 
including both children and adults will be excluded if 
they fail to clearly state the age of patients who experi-
enced ADRs.
We will also review ADR reports from pharmacovigi-
lance systems.
sEArch strAtEgy
We will search MEDLINE, PubMed, Cochrane Central 
Register of Controlled Trials, EMBASE, CINAHL and 
International Pharmaceutical Abstracts for papers 
describing ceftriaxone toxicity in neonates, infants, 
children and adolescents. The search strategy is 
specific for each database and includes a combination 
of the medical subject headings and free text terms for 
safety, ceftriaxone and neonates, infants and children 
(online supplementary appendix 1). It will include all 
languages. All searches will be from the beginning of 
the database until December 2016. We will look for 
additional studies in the reference lists of selected arti-
cles and contact authors for unclear information.
We will also search ADR spontaneous reporting 
systems to include: (1) warnings issued; (2) case 
reports of ADRs to ceftriaxone in children reported 
and (3) signal detection studies performed. The 
systems include WHO Pharmaceuticals Newsletter and 
VigiBase from WHO; FDA Drug Safety Newsletter Fact 
Sheet and FDA Medwatch Safety alert from America; 
Canadian Adverse Reaction Newsletter and Canada 
Vigilance Adverse Reaction Online Database from 
Canada; Database of Adverse Event Notifications, the 
Australian Adverse Drug Reactions and Medicines 
Safety Update from Australia; Centre for Adverse 
Reactions Monitoring from New Zealand; European 
Directorate for the Quality Medicines and European 
public assessment reports from Europe; Drug Safety 
Update, Alerts and recalls for drugs and medical 
devices, Safety warnings, alerts and recalls, and Safety 
public assessment reports from the United Kingdom 
and Adverse Drug Reaction Bulletin from China.
study rEcOrds
The literature search results will be uploaded to 
EndNote X7. Two reviewers will independently screen 
and select studies for possible inclusion in the study 
in two phases: title and abstracts as the first step and 
full text as the second step (MMH and Jiangmin). Any 
disagreements will be resolved by discussion and if 
needed a third reviewer (LNZ).
rIsk Of bIAs In IndIvIduAl studIEs
We will use the Cochrane risk of bias tool for RCTs and 
Newcastle-Ottawa Scale for case–control and cohort 
studies. The quality of cross-sectional study, case series 
and case reports will be assessed by tailored quality 
assessment tools developed jointly by the National 
Heart, Lung, and Blood Institute and Research 
Triangle Institute International of National Insti-
tutes of Health based on other tools from the Agency 
for Healthcare Research and Quality, the Cochrane 
Collaboration, the United States Preventive Services 
Task Force, the Scottish Intercollegiate Guidelines 
Network and the National Health Service Centre for 
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Reviews and Dissemination (online supplementary 
appendix 2) .16 22–24 No quality assessment will be done 
for reports from ADR monitoring system.
dAtA ExtrActIOn
Data will be extracted from all included studies using 
specifically developed data extraction forms. Extracted 
information will include: study information (study ID, 
citation, country, institution, contact information), confir-
mation of eligibility for review, method (study design, 
information of study quality according to quality assess-
ment criteria of different types of studies), participant 
and setting (sample size, inclusion criteria, diagnostic 
criteria, setting), intervention (medicine, route, dose), 
outcomes (type and severity of ADRs) and conclusion 
(authors’ conclusion on safety evaluation). For contin-
uous data, mean, SD and number of participants will be 
extracted. For categorical data, events and total number 
of participants will be extracted. Whenever possible, we 
will use the results from an intention-to-treat analysis. The 
author of the included studies will be contacted, when 
necessary, to gather relevant information.
dAtA AnAlysIs And synthEsIs
strategy for data synthesis
Relative risks will be measured in RCTs and cohort 
studies, ORs in case–control studies and reporting 
ORs in ADR spontaneous reporting systems.25 26 Only 
ADRs identified from two or more studies will be anal-
ysed. The relative risks of ADRs present in at least two 
RCTs and cohort studies will be calculated, and only 
the RR >1 with at least three cases will be included 
suggesting that more ADRs were associated with ceftri-
axone. Meta-analysis of the RCTs will be done using 
Revman. The data will be considered homogeneous if 
I2 ≤50%. Homogeneous data will be analysed using the 
fixed-effect model, whereas heterogeneous data will 
be analysed using the random-effect model. The inci-
dence of total ADRs and severe ADRs will be assessed 
separately. The χ2 test will be used to compare cases. 
P-values <0.05 will be considered statistically signifi-
cant for all analyses.
subgroup analyses
Subgroup analyses or, if applicable, metaregression anal-
yses will be performed for factors presumed to cause 
variations in outcomes including age and dosage regimen 
(total dosage and total course).
EthIcs And dIssEMInAtIOn
The result of this systematic review will be dissem-
inated by publication in a peer-reviewed journal. 
Ethical assessment is not needed because we will search 
and evaluate only existing sources of literature. Our 
findings should be of benefit to health professionals 
who prescribe ceftriaxone.
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